➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Masitinib

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Masitinib?

Masitinib is an investigational drug.

There have been 32 clinical trials for Masitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Mastocytosis, and Sclerosis. The leading clinical trial sponsors are AB Science and [disabled in preview].

Recent Clinical Trials for Masitinib
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19AB SciencePhase 2
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentAB SciencePhase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsAB SciencePhase 3

See all Masitinib clinical trials

Clinical Trial Summary for Masitinib

Top disease conditions for Masitinib
Top clinical trial sponsors for Masitinib

See all Masitinib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.